Please assess the completion status of the following clinical trial:

Trial Title: A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 20 weight-stable, non-diabetic subjects~Exclusion Criteria:~* Age \< 25 or \> 65 years (to avoid studying subjects who could have latent type 1 diabetes, or the effects of age extremes in subjects with normal or impaired fasting glucose).~* HbA1c ≥5.9%~* Use of glucose-lowering agents.~* For female subjects: positive pregnancy test at the time of enrollment or study~* History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.~* Active systemic illness or malignancy.~* Symptomatic macrovascular or microvascular disease.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Saline, Then Exendin-9,39 (Type: EXPERIMENTAL): A week or two after screening, participants were admitted to the CRTU and Saline was infused during a hyperglycemic clamp during which escalating doses of glucagon were infused. After completion of this study participants underwent a washout period of 2 weeks after which they were readmitted to the CRTU and Exendin-9,39 was infused at 300pmol/kg/min was infused during a hyperglycemic clamp during which escalating doses of glucagon were infused.
- Exendin-9,39, Then Saline (Type: EXPERIMENTAL): A week or two after screening, participants were admitted to the CRTU and Exendin-9,39 was infused at 300pmol/kg/min during a hyperglycemic clamp during which escalating doses of glucagon were infused. After completion of this study participants underwent a washout period of 2 weeks after which they were readmitted to the CRTU and Saline was infused during a hyperglycemic clamp during which escalating doses of glucagon were infused.

Based on this trial design, predict the completion outcome and termination type (if applicable).